LIANLU pushes lipid-soluble vitamin B1 supply for global supplement and pharma markets

LIANLU is positioning itself as a major China-based supplier of lipid-soluble vitamin B1 derivatives, including benfotiamine, for pharmaceutical, nutraceutical and clinical nutrition customers. The company says its manufacturing, testing and OEM/ODM capabilities are built to meet rising demand for higher-bioavailability ingredients across international markets.

Why it matters: - Lipid-soluble vitamin B1 derivatives are gaining traction because they can improve absorption and tissue retention compared with standard water-soluble thiamine forms. - Demand is rising across supplements, pharmaceuticals and clinical nutrition as formulators look for ingredients with stronger bioavailability and clearer technical documentation. - LIANLU is trying to capture that shift with a supply chain built around benfotiamine and other vitamin B1 derivatives.

What happened: - LIANLU introduced itself as a China-based supplier of lipid-soluble vitamin B1, with benfotiamine listed in its product portfolio. - The company says its business combines R&D, chemical testing, manufacturing, OEM and ODM services, sales, and self-operated import and export operations. - LIANLU also said it serves customers in more than 30 countries and regions, including North America, Europe, Asia-Pacific and the Middle East. - Direct international operations run through LIANLU USA Ltd in Pomona, California.

The details: - Conventional thiamine forms such as thiamine mononitrate and thiamine hydrochloride depend on active transport in the small intestine, which can saturate at higher doses. - Water-soluble thiamine is also rapidly excreted through the kidneys, which can limit how long it stays in target tissues. - Lipid-soluble derivatives like benfotiamine can pass through lipophilic cell membranes by passive diffusion and are then converted into active thiamine forms inside cells. - LIANLU says benfotiamine is used in nutraceutical, pharmaceutical and sports nutrition applications. - The company links benfotiamine to interest in metabolic wellness, peripheral nerve health, glucose metabolism, microvascular health, diabetic neuropathy and AGE pathways. - LIANLU lists ISO 9001, ISO 14001, ISO 45001, FSSC 22000, FSVP, NSF-GMP, Kosher and Halal among its certification and compliance systems. - The company says its R&D center is Shanghai Newsunow Chemical Co., Ltd., located in Jinshan District, Shanghai. - LIANLU says that R&D center has more than 30 researchers, led by two doctoral supervisors. - The company says the research team works on vitamin and derivative products and other specialty ingredients. - LIANLU identifies Jiangxi Lianlu Bio-Technology Co., Ltd. in Wanzai County, Yichun City, Jiangxi Province, as its manufacturing base. - The company says the Jiangxi site has more than 48,000 square meters of GMP-compliant production space and annual output capacity of 1,000 tons. - LIANLU says its laboratory setup includes physical and chemical testing labs, instrument testing labs and microbiology labs. - The company said laboratory upgrades completed in 2025 were intended to expand testing capabilities and support consistent product quality. - LIANLU offers OEM and ODM services, including custom premixes, coatings and finished dosage forms such as tablets, hard capsules and soft capsules. - The company also lists product development and brand development services. - LIANLU participates in industry events including CPHI Worldwide, Vitafoods Europe and SupplySide Global.

Between the lines: - The announcement reads as a positioning play in a market where buyers are demanding more than commodity raw materials. - By emphasizing certifications, lab capacity and international distribution, LIANLU is signaling that it wants to compete as a regulated, full-service ingredient supplier rather than only a bulk manufacturer. - The focus on benfotiamine reflects broader industry interest in ingredients that can justify premium pricing through performance and documentation.

What's next: - LIANLU says more product specifications, technical information and manufacturing services are available on its official website: More information. - The company is likely to lean on its Shanghai R&D center, Jiangxi production base and overseas presence as it pursues additional global customers. - Continued demand for higher-bioavailability vitamin ingredients may shape the company’s product and service expansion.

The bottom line: - LIANLU is betting that lipid-soluble vitamin B1, backed by manufacturing scale and quality systems, will remain a growth category in global health and nutrition supply chains.